Literature DB >> 29725534

Middle segment pancreatectomy for a solid serous cystadenoma diagnosed by MRCP and review of the literature: A case report.

Yuichiro Okumura1, Takehiro Noda1, Hidetoshi Eguchi1, Yoshifumi Iwagami1, Daisaku Yamada1, Tadafumi Asaoka1, Koichi Kawamoto1, Kunihito Gotoh1, Shogo Kobayashi1, Koji Umeshita2, Yasuji Hashimoto3, Yutaka Takeda4, Masahiro Tanemura5, Minoru Shigekawa6, Eiichi Morii7, Tetsuo Takehara6, Masaki Mori1, Yuichiro Doki1.   

Abstract

Solid serous cystadenoma of the pancreas is the rarest subtype of serous cystadenoma. Cystic structures are difficult to recognize by imaging studies. In the clinical setting, it is crucial to discriminate a solid serious cystadenoma from other solid pancreatic tumors. The present study reported a case of solid serous cystadenoma in which the magnetic resonance cholangiopancreatography (MRCP) findings were useful for diagnosis and decision-making regarding the surgical strategy, with a review of the previous reports of solid serous cystadenoma. A 50-year-old woman was referred to our hospital for investigation of a pancreatic body mass. A 2-cm hypervascular solid tumor was revealed by computed tomography. No typical radiological imaging findings of small cysts were detected, such as a honeycomb structure, and an adequate specimen could not be gained by biopsy under endoscopic ultrasonography. However, the tumor showed high intensity on MRCP, suggesting its cystic nature. A solid serous cystadenoma was suspected based on these radiological findings, and middle segment pancreatectomy was performed as a function-preserving surgery. The histological findings were compatible with a solid serous cystadenoma. In conclusion, MRCP imaging may be helpful for diagnosis and decision-making regarding the most appropriate surgical method for solid serous cystadenomas.

Entities:  

Keywords:  magnetic resonance cholangiopancreatography; pancreas; serous cystadenoma; serous cystic neoplasm; solid serous cystadenoma

Year:  2018        PMID: 29725534      PMCID: PMC5920357          DOI: 10.3892/mco.2018.1598

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


Introductiom

Serous cystadenoma (SCA) is fundamentally a multilobular cystic tumor that consists of a thin capsule and small cysts only millimeters in diameter. SCA constitutes approximately only 1 to 2% of all pancreatic tumors (1), but the number of patients with SCA has been growing due to the frequent use of radiography and recent improvements of imaging modalities. SCA is currently categorized into four subtypes: microcystic, macrocystic, mixed, and solid types. The most common subtype is microcystic type, and the cystic structure can be easily recognized in the former three subtypes. On the other hand, the solid type accounts for only 3% of all SCAs in a Japanese multicenter study (1), and it is described as noncystic, meaning that a cystic structure is too tiny to be detected macroscopically. Solid SCA is usually misdiagnosed preoperatively as neuroendocrine tumor (NET) (2). In several case reports, the authors reported that magnetic resonance cholangiopancreatography (MRCP) might be useful for preoperative diagnosis of SCA (3–5). However, it is generally considered difficult to preoperatively differentiate SCA from other solid pancreatic tumors by imaging modalities. The present report describes a rare case of solid SCA in which the magnetic resonance imaging (MRI) findings were very informative in the diagnosis and decision to perform middle segment pancreatectomy as an organ-preserving surgical strategy.

Case report

A 50-year-old woman was referred to the Department of Surgery in Osaka University Hospital for investigation of a pancreatic body mass detected during a health examination. She had no chief complaint. A benign thyroid tumor had been found, and she was followed up by annual ultrasonography. Physical examination revealed normal abdominal findings. Laboratory examination revealed no anemia, jaundice, or hyperglycemia. The serum level of carcinoembryonic antigen and carbohydrate antigen 19-9 were within the reference ranges, and no excess of pancreatic endocrine hormones, including insulin, glucagon, and gastrin, was observed. Contrast-enhanced computed tomography (CT) demonstrated a 2-cm solid mass in the body of the pancreas, which was strongly enhanced in the early phase (Fig. 1A). Fluorine-18 fluorodeoxyglucose positron emission tomography-CT showed no abnormal accumulation of the tracer in the tumor (Fig. 1B). Endoscopic ultrasonography (EUS) revealed a hypoechoic, heterogeneous, and hypervascular solid mass without posterior echo enhancement in the body of the pancreas, and no cystic component could be recognized (Fig. 1C and D). We performed EUS-guided fine needle aspiration (FNA) three times, but could not obtain adequate specimens for diagnosis because of contamination of blood. MRI clearly showed a round mass with low intensity on T1-weighted images (Fig. 2A) and high intensity on both T2-weighted images (Fig.2B) and diffusion-weighted images (Fig. 2C). MRCP showed high intensity, and the tumor signal intensity was similar to that of an incidentally detected hepatic cyst (Fig. 2D). We strongly suspected the tumor to be a solid SCA based on the radiological findings, including MRCP, but histological confirmation could not be gained. We finally performed middle segment pancreatectomy as a function-preserving surgery. The resected specimen was 2.6 cm in width, and surgical margin was ascertained by intraoperative ultrasonography (Fig. 3A). The cranial stump was cut off using a triple-row linear stapler and caudal stump was reconstructed by pancreaticogastrostomy using mattress sutures (6). The patient's recovery was complicated by pulmonary embolism (Grade 3 by Common Terminology Criteria for Adverse Events: CTCAE) and pancreatic fistula (Grade B by International Study Group of Pancreatic Fistula classification: ISGPF). The patient recovered with conservative treatment for pancreatic fistula and anti-coagulation therapy with warfarin for pulmonary embolism, and she was discharged on the 49 postoperative day.
Figure 1.

Computed tomography (CT) and abdominal ultrasonography. (A) Contrast-enhanced CT showed a well-enhanced solid tumor of 2 cm in the body of pancreas (arrow). (B) Positron emission tomography–CT showed no abnormal uptake (arrow). (C and D) Endoscopic ultrasonography showed a well circumscribed, hypoechoic, and hypervascular tumor without posterior echo enhancement.

Figure 2.

Magnetic resonance imaging. (A) low intensity on T1-weighted imaging (arrow), (B) high intensity on T2-weighted imaging (arrow), and (C) high intensity on diffusion-weighted imaging (arrow). (D) On a coronal magnetic resonance cholangiopancreatography image, the tumor showed high intensity (arrow), which was similar to that of the incidentally detected hepatic cyst (arrowhead).

Figure 3.

Resected specimen of the tumor. (A) Middle segment pancreatectomy was performed with enough surgical margin. (B) Macroscopic photograph of the pancreatic resection specimen, revealing a solid and glossy appearance with central fibrous tissue. The tumor measured 2.2 cm.

The pancreatic tumor was clearly circumscribed within the resected specimen, and the cut surface of the tumor was solid, glossy, and reddish with a central fibrous scar in a stellate pattern (Fig. 3B). It was 2.2 cm in size, and no honeycomb structure characteristic of small cysts was detected macroscopically. Formalin-fixed paraffin-embedded tissue sections were prepared, and immunohistochemical staining was conducted using following antibodies; anti-mucin 6 antibody (Leica Biosystems, Nussloch, Germany), anti-synaptophysin antibody, anti-chromogranin antibody (both from Dako, Glostrup, Denmark) and anti-Ki-67 antibody (Roche Diagnostics, Basel, Switzerland). Briefly, the sections were incubated at room temperature with anti-mucin 6 for 32 min, anti-synaptophysin for 16 min, anti-chromogranin A for 16 min and anti-Ki-67 for 16 min, respectively. Microscopic examination revealed numerous microcysts separated by hypocellular and dense collagen fibers. The inner surface of the cysts was lined by a single layer of cuboidal epithelium with clear cytoplasm (Fig. 4A). The cytoplasm was strongly stained by periodic acid-Schiff and digested by diastase because of the presence of abundant intracytoplasmic glycogen (Fig. 4B and C). The tumor cells were positive for mucin 6 (Fig. 4D) and negative for neuroendocrine differentiation labeling (synaptophysin (Fig. 4E) or chromogranin A (Fig. 4F). The Ki-67 labeling index was 1 to 2%, and there was no evidence of malignancy or lymph node metastasis. The final diagnosis was a solid SCA. She had been in follow-up by every three months laboratory check and every six months radiological check by CT. At the time of this writing (1 year postoperatively), the patient was clinically well with no evidence of recurrence. She had no diarrhea and weight loss without digestive enzymes. In addition, she also maintained favorable glucose tolerance without oral hypoglycemic agents or insulin. The preoperative and postoperative hemoglobin A1c level was not worsened (5.8 and 6.0%, respectively). This clinical research was approved by the Research Ethics Board of the Osaka University Research Committee and conducted according to Institutional Review Board guidelines. Written informed consent was obtained from the patient prior to publication of the present case report.
Figure 4.

Histological examination of the resected specimen. (A) Microscopically, the tumor was composed of numerous tiny cysts lined by a single layer of cuboidal epithelium with abundant fibrous stroma (hematoxylin and eosin stain, ×400). (B) The cytoplasm was strongly stained by periodic acid-Schiff stain (×400) and (C) digested by diastase (×400). The cells were positive for (D) mucin 6 (×400) and negative for (E) synaptophysin (×200) and (F) chromogranin A (×200).

Discussion

In 1978, Compagno and Oertel (7) first proposed the concept of serous cystic neoplasm of the pancreas. SCA is morphologically classified into four subtypes: microcystic, macrocystic, mixed, and solid types. The solid variant of SCA was first described by Perez-Ordonez et al (8) in 1996, who reported that the cells were arranged in small acini with no or minute central lumina, resembling a solid tumor. The characteristic radiological findings of SCA, such as a honeycomb appearance, polycystic pattern, lobularity, sunburst appearance (central calcification), and hemorrhage, are quite rare in solid SCA. Solid SCA is so rare that the incidence is only 3.0% of all SCAs, compared with microcystic type (58%) and macrocystic type (20%) (1). Whether solid SCA is a variant of SCA or a separate disease entity was historically controversial (5,8,9), but it is now considered a variant of SCA because the cytological and immunohistological features of this tumor are very similar to those of SCA. Compared with the microcystic type, which is composed of numerous tiny cysts (usually ~2–10 mm), the solid type is formed by far smaller cysts that cannot be recognized by the naked eye and shows a homogeneous and glossy appearance. We systematically reviewed the English literature by using PubMed and Google Scholar from 1995 to 2017. The keywords of ‘solid serous cystadenoma’, ‘solid-type serous cystadenoma’, ‘serous cystic neoplasm’ or ‘solid serous adenoma’ were used. We excluded the nonsurgical cases. To our knowledge, only 19 cases including our case have been published with a pathological confirmation (Table I) (2,3,5,8–19).
Table I.

Literature review of the clinicopathological findings of patients with solid-type serous cystadenomas.

No.AuthorsYearAge (years)SexSymptomsLocationSize (cm)EnhancementMRI (T1/T2/MRCP)Clinical diagnosisOperation(Refs.)
1Perez-Ordonez et al199670FAbdominal PainPt4.0NETDP(8)
2Kosmahl et al200450MPh2.5PPPD(10)
3Yamamoto et al200460MEpigastric distentionPh2.0YesLow/high/highNETPPPD(5)
4Gabata et al200559FAbdominal PainPb2.0YesLow/high/highSolid SCADP(3)
5Yamaguchi200658FNonePb2.0YesNETDP(9)
6Reese et al200666MNonePh4.0YesNETPPPD(11)
7Sanaka et al200774MNonePb1.6YesNETEnucleation(12)
8Stern et al200762MAbdominal PainPbh4.2NET, others[a]DP(13)
9Casadei et al200859FAbdominal PainPt4.0YesSolid SCADP(14)
10Yasuda et al200972FNonePh1.7Yes−/high/−NETPPPD(15)
11Hayashi et al201274FPb4.2Yes(16)
12Hayashi et al201257FPh2.1Yes(16)
13Hayashi et al201258FPb3.2Yes(16)
14Lee et al201356MNonePt2.5YesNETLaparoscopic DP(17)
15Kishida et al201358MNonePb2.8YesLow/high/highNETDP(18)
16Ishigami et al201443FPhYesLow/−/Not detected(19)
17Ishigami et al201465FPtbYes−/−/Not detected(19)
18Katsourakis et al201672FAbdominal PainPt3.0Yes−/−NETDP(2)
19Present case50FNonePb2.2YesLow/high/highSolid SCAMP

Others include pancreatic ductal adenocarcinoma, solid pseudopapillary tumor, and metastatic carcinoma; DP, distal pancreatectomy; F, female; M, male; MP, middle segment pancreatectomy; MRI, magnetic resonance imaging; NET, neuroendocrine tumor; Pb, pancreas body; Ph, pancreas head; Pt, pancreatic tail; PPPD, pylorus preserving pancreaticoduodenectomy; SCA, serous cystadenoma.

Some reports have described the radiological findings of solid SCA. A honeycomb structure is generally a typical finding of SCA; however, this finding cannot be detected in solid SCA even by EUS because the internal microlevel structure is difficult to capture. As a result, solid SCA is difficult to distinguish from other solid pancreatic tumors such as NET, acinar cell carcinoma, solid pseudopapillary tumor, and metastatic carcinoma. In most cases, NET is an especially important differential diagnosis because it is clinically the most common hypervascular solid tumor of the pancreas. Several case reports have shown that MRCP is a useful tool in distinguishing solid SCA from other solid pancreatic tumors (3–5). Solid SCA is reported to show T1 low intensity and T2 high intensity almost same as the other types of SCA (1). In general, MRCP involves heavily T2-weighted sequences, and the echo time is prolonged to about 10 times longer than regular T2-weighted imaging. On MRCP images, only a pure water cyst can gain hyperintensity. Both solid SCA and NET generally show hyperintensity on regular T2-weighted images. However, only solid SCA maintains this high intensity because of its cystic nature on MRCP. The high intensity on MRCP is quite a useful clue for clearly differentiating solid SCA from NET. MRI is becoming as common as CT for diagnostic modality. It can provide large amounts of valuable anatomical information preoperatively (20–22). If a tumor reveals high intensity on MRCP, this indicates that the tumor is composed mainly of not a solid substance but rather a watery fluid. In the present case, the signal intensity of the tumor was similar to that of the incidentally detected hepatic cyst. This finding could also be valuable for reaching the accurate preoperative diagnosis. With respect to treatment, expectant management has been proposed when SCA is small and definitely diagnosed because this neoplasm grows slowly and there is a minimal risk of malignant transformation (23). When nonoperative management is selected, histological examination by EUS-FNA is recommended to provide essential information in advance, but an adequate specimen can be rarely obtained by EUS-FNA. The role of EUS-FNA is to obtain preoperative cytological confirmation of pancreatic malignant tumors (24), and tumor markers and DNA analysis of cyst aspirates are reportedly helpful in improving diagnostic yield (25). EUS-FNA is recommended for NET as an informative tool in differentiating from other pancreatic tumors because of its high diagnostic sensitivity, which is reported as high as 87–90% (26–28). However, the reported diagnostic accuracy of EUS-guided biopsy for cystic tumors of the pancreas ranges from 17–21% (18,29–31), and the specimen often lacks the epithelial tissue necessary for diagnosis because of its cystic nature. Consequently, EUS-FNA alone is unlikely to provide the high level of diagnostic evidence necessary to support observational management. The indication for EUS about solid SCA is not mentioned because of its rarity in the guidelines about pancreatic cysts (25,32–34). In the present case, the tumor was initially deemed a NET because of its hypervascularity and solid appearance. However, the MRCP finding strongly indicated the possibility of solid SCA. We tried to gain histological confirmation by EUS-FNA, but ended up as a failure, and the possibility of NET could not be excluded. We finally selected surgical intervention because solid SCA is rare and the final diagnosis ought to be based on histological confirmation of a surgical specimen unless the diagnosis is preoperatively assured by EUS-FNA. We performed middle segment pancreatectomy as a function-preserving surgery because the tumor was as small as 2.2 cm. An organ-preserving surgical procedure is generally recommended for SCA because lymph node metastasis of SCA is quite rare and lymphadenectomy is not necessary (35). In previous reports of SCA with clear mention about operative procedure, all of the 13 patients underwent pancreaticoduodenectomy, distal pancreatectomy, or enucleation (Table I). Previous five cases lacked in operation method, as those reports placed value in the imaging pitfalls of solid SCA. Therefore, Our case is the first in which middle segment pancreatectomy was performed for a solid SCA as an organ-preserving surgery, and this procedure might lead to better preservation of endocrine function (36). Solid SCA of the pancreas is definitively a rare disease, but oncologic surgeons should be aware of the characteristics of this neoplasm to allow for a correct preoperative diagnosis. Further investigation to accumulate more evidence regarding this rare disease is expected. We experienced a case of solid SCA of the pancreas for which MRCP imaging was very helpful for accurate diagnosis and decision-making regarding the surgical method.
  33 in total

1.  Solid serous adenoma of the pancreas: a solid variant of serous cystadenoma or a separate disease entity?

Authors:  Masahiko Yamaguchi
Journal:  J Gastroenterol       Date:  2006-02       Impact factor: 7.527

2.  Solid serous adenoma of the pancreas: a rare form of serous cystadenoma.

Authors:  Madhusudhan R Sanaka; Thomas E Kowalski; Corey Brotz; Charles J Yeo; Peter McCue; Juan Palazzo
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

3.  A case of solid-type serous cystadenoma mimicking neuroendocrine tumor of the pancreas.

Authors:  Yoshihiro Kishida; Hiroyuki Matsubayashi; Yukiyasu Okamura; Katsuhiko Uesaka; Keiko Sasaki; Hiroaki Sawai; Kenichiro Imai; Hiroyuki Ono
Journal:  J Dig Dis       Date:  2014-04       Impact factor: 2.325

4.  Cystic duct with no visible signal on magnetic resonance cholangiography is associated with laparoscopic difficulties: an analysis of 695 cases.

Authors:  Yasuhito Shimizu; Taiichi Otani; Jun Matsumoto; Kijuro Takanishi; Tomohito Minami; Hiroko Tsunoda; Masaru Miyazaki
Journal:  Surg Today       Date:  2013-09-12       Impact factor: 2.549

5.  Fine-needle aspiration of pancreatic serous cystadenoma: cytologic features and diagnostic pitfalls.

Authors:  Pochi Huang; Gregg Staerkel; Nour Sneige; Yun Gong
Journal:  Cancer       Date:  2006-08-25       Impact factor: 6.860

6.  Multicenter study of serous cystic neoplasm of the Japan pancreas society.

Authors:  Wataru Kimura; Toshiyuki Moriya; Ichiro Hirai; Keiji Hanada; Hideki Abe; Akio Yanagisawa; Noriyoshi Fukushima; Nobuyuki Ohike; Michio Shimizu; Takashi Hatori; Naotaka Fujita; Hiroyuki Maguchi; Yasuhiro Shimizu; Kenji Yamao; Tamito Sasaki; Yoshiki Naito; Satoshi Tanno; Kosuke Tobita; Masao Tanaka
Journal:  Pancreas       Date:  2012-04       Impact factor: 3.327

Review 7.  Solid serous adenoma of the pancreas: an uncommon but important entity.

Authors:  M C Machado; M A Machado
Journal:  Eur J Surg Oncol       Date:  2008-04-25       Impact factor: 4.424

8.  Serous cystadenoma of the pancreas: limitations and pitfalls of endoscopic ultrasound-guided fine-needle aspiration biopsy.

Authors:  Nicole A Belsley; Martha B Pitman; Gregory Y Lauwers; William R Brugge; Vikram Deshpande
Journal:  Cancer       Date:  2008-04-25       Impact factor: 6.860

9.  Solid variant of serous cystadenoma of the pancreas.

Authors:  Akira Yasuda; Hirozumi Sawai; Nobuo Ochi; Yoichi Matsuo; Yuji Okada; Hiromitsu Takeyama
Journal:  Arch Med Sci       Date:  2011-05-17       Impact factor: 3.318

10.  Solid Serous Adenoma of the Pancreas: A Case Report and Review of the Literature.

Authors:  Anastasios Katsourakis; Ioannis Dimitriou; Georgios Noussios; Iosiph Chatzis; Efthimios Chatzitheoclitos
Journal:  Case Rep Surg       Date:  2016-07-25
View more
  1 in total

1.  Pseudo solid-appearing pancreatic serous microcystic adenomas: Histologic diagnosis with the EUS core biopsy fork-tip needle.

Authors:  Erminia Manfrin; Claudia Perini; Serena Di Stefano; Laura Bernardoni; Alice Parisi; Luca Frulloni; Sokol Sina; Andrea Remo; Armando Gabbrielli; Stefano Francesco Crinò
Journal:  Endosc Ultrasound       Date:  2019 Sep-Oct       Impact factor: 5.628

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.